Hospital Universitario San Ignacio

Running trials

• Not yet recruiting

  Efficacy of the Use of Real-time Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes and Stage 3 and 4 Chronic Kidney Disease.

  NCT07668219· Hospital Universitario San Ignacio· Source

• Not yet recruiting

  Influence of the Use of Specific Nutritional Formulas on Time in Range in Patients With Type 2 Diabetes

  NCT07666581· Hospital Universitario San Ignacio· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

  NCT07409181· Phase 2· Boehringer Ingelheim· Source

• Recruiting

  LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

  NCT07415044· Phase 2· Eli Lilly and Company· Source

• Not yet recruiting

  Real-time Continuous Glucose Monitoring Compared With Intermittent Continuous Glucose Monitoring in People With Type 2 Diabetes Treated With Insulin.

  NCT07308925· Hospital Universitario San Ignacio· Source

• Recruiting

  Characterization, Health Resource Utilization and Biomarkers in Early-stage

  NCT07703631· Hospital Universitario San Ignacio· Source

• Active, not recruiting

  Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

  NCT07087054· Phase 3· Crinetics Pharmaceuticals Inc.· Source

• Not yet recruiting

  Comparison of SmartGuard vs Temp Target in Patients With Type 1 Diabetes Users of Advanced Hybrid Closed Loop System (AHCL) in Anaerobic Physical Activity.

  NCT06728423· Hospital Universitario San Ignacio· Source

• Recruiting

  A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

  NCT07190248· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

  NCT06920004· Phase 3· argenx· Source

• Active, not recruiting

  A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

  NCT07044297· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

  NCT06997497· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

  NCT06798012· Phase 2· Takeda· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819891· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

  NCT06935357· Phase 3· Biogen· Source

• Recruiting

  A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

  NCT06717347· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

  NCT06623422· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

  NCT06561386· Phase 3· Bristol-Myers Squibb· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)

  NCT05170204· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)

  NCT05262023· Phase 1/2· Denali Therapeutics Inc.· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis

  NCT04221477· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients

  NCT03127631· McMaster University· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer4 recruiting
• Type 2 diabetes3 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)2 recruiting
• Chronic kidney disease1 recruiting
• Colorectal cancer1 recruiting
• Crohn's disease1 recruiting
• IgA nephropathy1 recruiting
• Lupus (SLE)1 recruiting
• Obesity1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Type 1 diabetes1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Completed

  Efficacy of Intermittent Fasting Versus Continuous Caloric Restriction in the Treatment of Significant Weight Regain After Bariatric Surgery

  NCT06766747· Hospital Universitario San Ignacio· Source

• Completed

  Efficacy and Safety of the Minimed 780G® Advanced Hybrid Closed Loop System (AHCL) in Patients With Type 1 Diabetes Undergoing Surgery

  NCT06947031· Hospital Universitario San Ignacio· Source

• Completed

  Prevalence and Genotype Distribution of HPV Infection Among People Living With HIV in Colombia

  NCT07934992· Hospital Universitario San Ignacio· Source

• Completed

  A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

  NCT04732221· Phase 2/3· Merck Sharp & Dohme LLC· Source

• Completed

  A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)

  NCT04729907· Phase 3· Biogen· Source

• Completed

  Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

  NCT04435626· Phase 3· Bayer· Source

• Completed

  A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)

  NCT03992430· Phase 3· Sarepta Therapeutics, Inc.· Source

• Completed

  Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy

  NCT04089566· Phase 3· Biogen· Source

• Completed

  Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)

  NCT04233879· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

  NCT03473223· Phase 3· CSL Behring· Source

• Completed

  Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

  NCT03036488· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

  NCT01909453· Phase 3· Pfizer· Source